Advertisement
NEW YORK, Nov. 9, 2017 /PRNewswire/ -- Read the full report: https://www.reportlinker.com/p05175254
Learn what your team gets right, and where it's going wrong in Medical Affairs Reputations: Melanoma (US).Comparing 8 major melanoma treatments from Amgen, Bristol-Myers Squibb, Merck & Co., Novartis, and Roche this report reveals:
Find out what more doctors want from your medical affairs team including:
How doctors rate your team overall, and on 12 key medical affairs services.Which medical affairs services are most important, and what you can do to improve them.How, and how often doctors want to meet with your team.
That's actionable information you can use to turn your team into one that doctors rely on.
Insight into Medical Affairs Teams for These Melanoma Treatments
Cotellic (cobimetinib; Roche)Imlygic (talimogene laherparepvec; Amgen)Keytruda (pembrolizumab; Merck & Co.)Mekinist (trametinib; Novartis)Opdivo (nivolumab; Bristol-Myers Squibb)Tafinlar (dabrafenib; Novartis)Yervoy (ipilimumab; Bristol-Myers Squibb)Zelboraf (vemurafenib; Roche)
An Expert-designed Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important questions like:
What do doctors need?
How, and how often are they using your medical affairs team? What services do they consider most important? How often should you contact them? What channels are best?
Does your medical affairs team deliver?
How memorable are your team's interactions with doctors? How do doctors rank your team for performance and satisfaction in 12 key areas? How does your team compare to the competition—in each area, and overall?
What needs improvement?
Are you delivering the services that are most important to doctors? Where do you need to improve? How can your team enhance its services?
Based on Interviews with Practicing Doctors
We surveyed 100 US medical oncologists and dermato-oncologists, chosen from the largest community of validated physicians in the world
All respondents:
Have been practicing for between 3 and 35 yearsSee at least 5 patients with melanoma in a typical monthDevote at least 50% of their time to direct patient careHave interacted with at least one listed product's medical affairs team in the past 6 months.
We conducted the survey between June 1st and June 7th, 2017.
Read the full report: https://www.reportlinker.com/p05175254
About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
Advertisement
Learn what your team gets right, and where it's going wrong in Medical Affairs Reputations: Melanoma (US).Comparing 8 major melanoma treatments from Amgen, Bristol-Myers Squibb, Merck & Co., Novartis, and Roche this report reveals:
Find out what more doctors want from your medical affairs team including:
How doctors rate your team overall, and on 12 key medical affairs services.Which medical affairs services are most important, and what you can do to improve them.How, and how often doctors want to meet with your team.
That's actionable information you can use to turn your team into one that doctors rely on.
Insight into Medical Affairs Teams for These Melanoma Treatments
Cotellic (cobimetinib; Roche)Imlygic (talimogene laherparepvec; Amgen)Keytruda (pembrolizumab; Merck & Co.)Mekinist (trametinib; Novartis)Opdivo (nivolumab; Bristol-Myers Squibb)Tafinlar (dabrafenib; Novartis)Yervoy (ipilimumab; Bristol-Myers Squibb)Zelboraf (vemurafenib; Roche)
An Expert-designed Competitive View of Your Medical Affairs Team
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams—answering important questions like:
What do doctors need?
How, and how often are they using your medical affairs team? What services do they consider most important? How often should you contact them? What channels are best?
Does your medical affairs team deliver?
How memorable are your team's interactions with doctors? How do doctors rank your team for performance and satisfaction in 12 key areas? How does your team compare to the competition—in each area, and overall?
What needs improvement?
Are you delivering the services that are most important to doctors? Where do you need to improve? How can your team enhance its services?
Based on Interviews with Practicing Doctors
We surveyed 100 US medical oncologists and dermato-oncologists, chosen from the largest community of validated physicians in the world
All respondents:
Have been practicing for between 3 and 35 yearsSee at least 5 patients with melanoma in a typical monthDevote at least 50% of their time to direct patient careHave interacted with at least one listed product's medical affairs team in the past 6 months.
We conducted the survey between June 1st and June 7th, 2017.
Read the full report: https://www.reportlinker.com/p05175254
About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
https://www.reportlinker.com
__________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/medical-affairs-reputations-melanoma-us-2017-300553533.html
SOURCE Reportlinker
